PhaseRx Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
PZRXQ
PhaseRx General Information
Description
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Contact Information
Website
www.phaserx.comCorporate Office
- 410 West Harrison Street
- Suite 300
- Seattle, WA 98119
- United States
Corporate Office
- 410 West Harrison Street
- Suite 300
- Seattle, WA 98119
- United States
PhaseRx Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 5.44K |
PhaseRx Financials Summary
As of 30-Sep-2017, PhaseRx has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2017 | FY 2016 31-Dec-2016 | FY 2015 31-Dec-2015 | FY 2014 31-Dec-2014 |
|---|---|---|---|---|
| EV | 7,111 | 5,096 | ||
| Revenue | 0 | 0 | 375 | 1,200 |
| EBITDA | (12,955) | (18,004) | (5,397) | (4,970) |
| Net Income | (13,891) | (20,137) | (7,377) | (6,849) |
| Total Assets | 6,038 | 16,448 | 3,914 | 2,659 |
| Total Debt | 5,441 | 5,703 | 19,841 | 12,540 |
PhaseRx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PhaseRx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
PhaseRx Comparisons
Industry
Financing
Details
PhaseRx Competitors (1)
One of PhaseRx’s competitors is Oxb, a Corporation company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oxb | Corporation | Oxford, United Kingdom |
PhaseRx Patents
PhaseRx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018126084-A1 | Branched peg molecules and related compositions and methods | Inactive | 30-Dec-2016 | ||
| CA-2974503-A1 | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells | Inactive | 21-Jan-2015 | ||
| JP-2021050212-A | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells | Active | 21-Jan-2015 | ||
| WO-2016118697-A1 | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells | Inactive | 21-Jan-2015 | ||
| WO-2016118697-A9 | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells | Inactive | 21-Jan-2015 | A61K31/7105 |
PhaseRx Signals
PhaseRx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PhaseRx FAQs
-
When was PhaseRx founded?
PhaseRx was founded in 2006.
-
Where is PhaseRx headquartered?
PhaseRx is headquartered in Seattle, WA.
-
What is the size of PhaseRx?
PhaseRx has 21 total employees.
-
What industry is PhaseRx in?
PhaseRx’s primary industry is Biotechnology.
-
Is PhaseRx a private or public company?
PhaseRx is a Public company.
-
What is PhaseRx’s stock symbol?
The ticker symbol for PhaseRx is PZRXQ.
-
Who are PhaseRx’s competitors?
Oxb is a competitor of PhaseRx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process